Therapies that target immune checkpoints, such as programmed cell death-1 (PD-1) and CTL-associated antigen-4 (CTLA-4), have been approved for use in a variety of tumor types, including NSCLC [4]. This evidence concerns the gene CTLA4 and neoplasm.